Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-16
    E.g., 2018-08-16

Articles

19358 items
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

The Pryor-Cohen letter

The Pryor-Cohen letter The lawmakers appended four questions arising from prior contacts with the company, which Berlex said it intends to answer this week. The questions are not included here because the context is not...
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

White House handbook for selling health plan

White House handbook for selling health plan WASHINGTON - A briefing book on the Clinton administration's planned health care reforms, which the White House distributed to Democratic members of Congress last week, contains strongly worded...
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

A real pot-boiler

A real pot-boiler A CEO once told us that his job was to turn the heat up under the pot of water, and keep turning it up until the water roiled up and splattered over...
12:00 AM, Aug 16, 1993  |  BioCentury | Product Development

CTII's cell therapy for diabetes

Noteworthy CTII's cell therapy for diabetes CytoTherapeutics Inc. was to announce today that it has begun Phase I trials of polymer-encapsulated islet cells that will be implanted in patients with Type I insulin-dependent diabetes and...
12:00 AM, Aug 16, 1993  |  BioCentury | Finance

Dampening expectations

Noteworthy Dampening expectations Regeneron Pharmaceuticals Inc. stock responded negatively to the company's disclosure last week that there was no significant difference between drug and placebo in its Phase II trial of ciliary neurotrophic factor to...
12:00 AM, Aug 09, 1993  |  BioCentury | Product Development

Adjuvants key to biotech vaccines

A decade ago, interest in vaccines languished as liability issues drove most companies out of the business. But the resolution of those issues, the advent of AIDS and the return of tuberculosis have stimulated renewed...
12:00 AM, Aug 09, 1993  |  BioCentury | Strategy

Low-tech solution to longer shelf-life

Low-tech solution to longer shelf-life In ag biotech even more than in pharmaceuticals, low-tech, low-priced products are likely to jostle for consumer acceptance along with high-tech, high-priced goods. Fruits and vegetables are already commodities, and...
12:00 AM, Aug 09, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Elan Corp. plc (ELN) Jerry Treppel of Kidder, Peabody initiated coverage of with a "strong buy." Treppel said ELN is the best-positioned of the major drug delivery companies in terms of product, hence revenue diversification...
12:00 AM, Aug 09, 1993  |  BioCentury | Product Development

A glossary of adjuvants

A glossary of adjuvants Non-proprietary Alum QS-21 Stimulon (Cambridge Biotech) - derived from soapbark tree, Quillaja saponaria Optivax (CytRx) - copolymer emulsion MPL (Ribi ImmunoChem) - monophosphoryl lipid A, a modified form of lipid A derived from bacterial endotoxin TLC A-60...
12:00 AM, Aug 09, 1993  |  BioCentury | Strategy

How DNAP tested its tomatoes

How DNAP tested its tomatoes DNA Plant Technology Corp., which last week reported better-than-expected consumer response to its FreshWorld Farms tomatoes, used a passive marketing strategy in the recently completed market tests. "We pretty much just...

Pages